Ocotober 10, 2012 -- Scientists will present new findings that suggest a chemical found in red wine can help prevent
cancer, heart disease and diabetes at an international conference. Resveratrol 2012 is an
international conference due to be held at the University of Leicester in December.
It brings together researchers from all over the world to share, discuss and summarize the last two
years of scientific work in the area of resveratrol – a compound found in grapes and red wine.
The red wine miracle compound, resveratrol, is keeping both scientists and the health industry very
busy. Since 2010, a number of clinical trials have shown potential disease prevention effects for
resveratrol in humans. Evidence from more than ten of these recent clinical trials will be presented
and discussed at Resveratrol 2012, the 2nd International Scientific Conference on Resveratrol and
Health, at Leicester University, 5-7 December, 2012.
Even though resveratrol is a comparatively simple compound found in wine, grapes, peanuts and
berries, it has complex and beneficial effects on the human body. Recommendations from the first
international conference on resveratrol held in Denmark, Resveratrol2010, were that the benefits
seen in animal models had to be proven in humans. At that time there was not yet a scientific basis
to say that resveratrol has a disease preventative or therapeutic effect in humans, nor that
resveratrol could extend human life. The scientific working group from Resveratrol2010 recognized
the strong preventive effects of resveratrol as observed in experimental animals in four areas:
Cancer in the colon and skin, Coronary-hearth disease, Diabetes, and Neuro-protection. The big
issue in 2010 was that no human trials on resveratrol were available.
Therefore, the scientific working group from Resveratrol2010 recommended initiating human
clinical trials to test the preventive effect of resveratrol. A number of clinical trials have now been
established since September 2010. While these trials involve only small numbers of participants
receiving short-term access to resveratrol, the most crucial findings are that these first clinical
trials support the preventive effects already established in experimental animals.
Now, two years later, the 2nd International Scientific Conference on Resveratrol and Health,
Resveratrol2012, will take place in Leicester, UK, in December 2012. Here, data from more than
ten of these clinical trials will be presented and discussed. These new clinical trials will be
invaluable for the formulation of the next set of recommendations for resveratrol.
The chair of the Scientific Committee for Resveratrol2012, Associate Professor Ole Vang, Roskilde
University, Denmark, recalls, “A few months before our conference in 2010, I suggested that a
number of clinical trials on resveratrol would be presented at this first conference, but only a
single human study concerning treatment with resveratrol for one month was included. I was little
disappointed at that time. But over the last two years the clinical data has started to roll in”.
At Resveratrol2012, there will be more than 65 lectures, presentations and posters by different
researchers from all over the world. The leading names in the area of resveratrol will be present to
set the agenda for resveratrol market, R&D as well as innovation for the next coming years.
Resveratrol2012 will bring together researchers and experts from all over the world to share,
discuss and summarize the last two years of scientific work in the area of resveratrol. Other than
offering great opportunities for knowledge sharing and networking, the conference will produce a
selection of reports with the latest update on global resveratrol research, as well as the next set of
recommendations for the coming year's scientific research and the use of resveratrol.
For the program and other details please visit http://www.resveratrol2012.eu/
For more information:
Assoc. Prof. Ole Vang
+45 4674 2552